Iptacopan's 82.3% haemoglobin-response rate has not reached a single GCC formulary, and fewer than 15 labs across six countries can even diagnose PNH.
Anti-C5 complement inhibitors (eculizumab/Soliris and ravulizumab/Ultomiris, both AstraZeneca/Alexion) are the GCC standard of care for PNH, covered under Saudi Arabia's National Programme for Rare Genetic Diseases (NPHC) and the UAE Ministry of Health rare-disease formulary. Access is gated by specialist-centre designation: patients with confirmed PNH (LDH ≥2× ULN plus a FLAER-positive clone ≥10%) are treated only at King Abdulaziz Medical City (Riyadh), King Faisal Specialist Hospital & Research Centre (Riyadh/Jeddah), Abu Dhabi's AUH, and Rashid Hospital (Dubai) — concentrating the addressable patient base in four institutions across six countries and creating a significant travel burden for patients outside those cities.
Novartis's iptacopan (Fabhalta), FDA-approved in 2023 on an 82.3% haemoglobin-responder rate in APPLY-PNH, has not reached a single GCC formulary as of this writing. SFDA and MOHAP registration for novel rare-disease agents typically lags FDA/EMA approval by 12 to 24 months, and current access runs through named-patient compassionate use at select centres only. The oral-versus-IV switch dynamic now reshaping US and EU PNH access has not yet begun in the GCC. The region's underlying epidemiology compounds the opportunity for whoever registers first: the Saudi National Rare Disease Registry (SNRHD) tracks roughly 400 confirmed PNH cases, but consanguinity rates of 25–50% across KSA, UAE, and Qatar are estimated to elevate true PNH prevalence 20–30% above the global average, and fewer than 15 laboratories across all six GCC states offer FLAER flow cytometry, the gold-standard PNH diagnostic, leaving an estimated 40–50% of patients undiagnosed for more than three years.
PNH agents in the GCC — registration and access status, 2026
| Drug (Brand / INN) | Mechanism | Company | GCC Registration | Key Trial Result | GCC Access Status |
|---|---|---|---|---|---|
| Soliris / Ultomiris (eculizumab / ravulizumab) | Anti-C5 complement inhibitor — IV | AstraZeneca / Alexion | SFDA-registered (eculizumab from 2007; ravulizumab 2021+) | TRIUMPH / HERCULES — standard of care for haemolysis-predominant PNH | NPHC (Saudi) and MOH UAE covered; access limited to KAMC/KFSH&RC (Riyadh/Jeddah), AUH (Abu Dhabi), Rashid Hospital (Dubai) |
| Fabhalta (iptacopan) | Oral Factor B inhibitor | Novartis | FDA 2023; SFDA/MOHAP registration expected 12–24 months post-FDA | APPLY-PNH — 82.3% Hgb responder rate vs anti-C5 background | Not on any GCC formulary as of this writing; compassionate-use access only at select centres |
Sources: FDA Drugs@FDA; NEJM APPLY-PNH (Risitano et al. 2023); SNRHD annual report 2022; Al-Jishi EA et al. Saudi Med J 2020; NPHC Saudi Arabia 2023 programme documentation; MOH UAE rare disease formulary 2023.
What this brief answers
Every section answers a named commercial question your team is asking, scoped to your asset.
Delivers
- NPHC (Saudi) and MOH UAE coverage criteria (LDH and FLAER clone thresholds)
- Full specialist-centre list gating access across KSA, UAE, Qatar, Kuwait, Oman, Bahrain
- Patient travel-burden and referral pathway from non-designated cities
- Iptacopan compassionate-use precedent and what a formal switch protocol would require
Delivers
- SFDA independent-pathway registration timeline benchmarked against comparable rare-disease launches
- NPHC and MOH UAE formulary submission process for oral vs IV complement inhibitors
- Tender/NUPCO considerations for government-hospital procurement
- Competitive window analysis before oral Factor B inhibition reaches the market
Delivers
- FLAER flow cytometry lab capacity mapping across the six GCC states
- Consanguinity-adjusted prevalence modelling vs the ~400-patient registered base
- Diagnostic-delay analysis (est. 40–50% of patients undiagnosed >3 years)
- Recommendations for diagnostic-access partnerships to expand the identified patient pool
Custom brief delivered in 72 hours.
Commission This BriefWhat's inside
- How access to anti-C5 therapy is gated by specialist-centre designation at just four institutions, KAMC, KFSH&RC, AUH, and Rashid Hospital, across six GCC countries.
- Why patients with confirmed PNH, LDH at least 2x ULN plus a FLAER-positive clone of 10% or more, face a significant travel burden outside Riyadh, Jeddah, Abu Dhabi, or Dubai.
- Soliris and Ultomiris (AstraZeneca/Alexion), SFDA-registered since 2007 and 2021 respectively, anchored by TRIUMPH and HERCULES trial data as the GCC standard of care.
- Fabhalta (iptacopan), Novartis's oral Factor B inhibitor FDA-approved in 2023 on an 82.3% haemoglobin-responder rate in APPLY-PNH, has not reached a single GCC formulary.
- Why consanguinity rates of 25 to 50% across KSA, UAE, and Qatar are estimated to elevate true PNH prevalence 20 to 30% above the global average, against the SNRHD's roughly 400 registered cases.
- How fewer than 15 laboratories across all six GCC states offer FLAER flow cytometry, leaving an estimated 40 to 50% of patients undiagnosed for more than three years.
- Why SFDA and MOHAP registration for novel rare-disease agents typically lags FDA and EMA approval by 12 to 24 months, delaying iptacopan's formal GCC entry.
- How iptacopan access today runs only through named-patient compassionate use, since the oral-versus-IV switch dynamic reshaping US and EU PNH access has not yet begun in the GCC.
- What NPHC (Saudi) and MOH UAE coverage criteria, including LDH and FLAER-clone thresholds, govern anti-C5 reimbursement across GCC payers today.
- How NUPCO tender and government-hospital procurement dynamics shape the path a newly registered agent, such as iptacopan, would need to follow for formulary listing.
- Which four specialist centres, KAMC and KFSH&RC in Saudi Arabia, AUH in Abu Dhabi, and Rashid Hospital in Dubai, anchor current anti-C5 prescribing across the GCC.
- Why compassionate-use access to iptacopan today runs through the same select specialist centres already prescribing anti-C5 therapy, ahead of any formal GCC registration.
Included with every brief
How AXLRx builds this brief
Prepared by MoatRx analysts.
Every AXLRx brief is built from primary regulatory sources (FDA Drugs@FDA, SFDA and MOH programme documentation), peer-reviewed literature, and GCC-specific registry and access data — not secondary summaries. Findings are independently verified before inclusion; if a figure cannot be sourced to a live record, it does not ship.
GCC PNH CI sources: FDA Drugs@FDA, APPLY-PNH (NEJM 2023), HERCULES (Blood 2019), SNRHD (Saudi National Rare Disease Registry) 2022 annual report, NPHC Saudi Arabia 2023 programme documentation, MOH UAE rare disease formulary 2023, the GCC rare disease diagnostic network survey (2021), Tarawah A et al. (Hematol Oncol Stem Cell Ther 2019), and Al-Jishi EA et al. (Saudi Med J 2020).
- Drug approval and SFDA registration status verified against FDA Drugs@FDA and NPHC/MOH UAE programme documentation
- Clinical trial results verified against published primary sources (APPLY-PNH, NEJM 2023; HERCULES, Blood 2019)
- PNH registry and prevalence figures verified against SNRHD annual report 2022 and Al-Jishi EA et al., Saudi Med J 2020
- FLAER diagnostic capacity verified against the GCC rare disease diagnostic network survey 2021 and Tarawah A et al., Hematol Oncol Stem Cell Ther 2019
Frequently asked questions
Commission this brief
AXLRx delivers GCC PNH competitive intelligence built for pharma and biotech commercial, access, and medical affairs teams entering the Gulf. Custom brief in 72 hours.
Use the intake form to specify your indication, geography, and commercial question.
AXLRx analyst confirms scope, comparators, and delivery format.
Research-verified brief in 72 hours with optional analyst readout.